Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head ...

Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...